Methicillin-resistant Staphylococcus aureus (MRSA)

Specific investigations
First-line therapy
Second-line therapy
A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M, Sorensen SV, Liu LZ. Clin Ther 2007; 29: 469–77.
At least for hospitalized patients, linezolid therapy may be less expensive than vancomycin.
Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ, Jones RN. Diagn Microbiol Infect Dis 2009; 64: 177–84.
Dalbavancin remains a viable second-line option for skin infections, including those caused by MRSA.
Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009.
Utili R, Cogo A, Cristini F, Prisco V, Sagnelli E, Tascini, et al. J Chemother 2012; 24: 113–21.
Daptomycin continues to represent a viable second-line option for treatment of MRSA infections.